Safety study pushes back phase 3 trial of Newron’s schizophrenia drugSwitzerland’s neurology specialist Newron must hold off starting a phase 3 study of its schizophrenia drug evenamide to Share XSafety study pushes back phase 3 trial of Newron’s schizophrenia drughttps://pharmaphorum.com/news/safety-trial-pushes-back-phase-3-trial-of-newrons-schizophrenia-drug/
FDA grew too close to Biogen during Alzheimer’s drug development, doctors sayThe FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its Share XFDA grew too close to Biogen during Alzheimer’s drug development, doctors sayhttps://pharmaphorum.com/news/fda-grew-too-close-to-biogen-during-alzheimers-drug-development-doctors-say/
Roche stops dosing in trial of Huntington’s disease hopeful tominersenRoche has stopped dosing in a phase 3 trial of tominersen, a potential Huntington’s disease (HD) drug developed Share XRoche stops dosing in trial of Huntington’s disease hopeful tominersenhttps://pharmaphorum.com/news/roche-stops-dosing-in-huntingtons-disease-trial/
COVID-19 increased demands on carers’ wellbeing, study findsCOVID-19 has increased demands on informal carers and severely increased demands on their mental, physical and financial wellbeing, Share XCOVID-19 increased demands on carers’ wellbeing, study findshttps://pharmaphorum.com/news/covid-19-increased-demands-on-informal-carers-wellbeing-study-finds/
Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systemsInjected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get Share XIpsen’s John Chaddock on making neurotoxins a priority for healthcare systemshttps://pharmaphorum.com/r-d/views-analysis-r-d/ipsens-john-chaddock-on-making-neurotoxins-a-priority-for-healthcare-systems/
Early data back J&J and AC Immune’s Alzheimer’s jabShares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s Share XEarly data back J&J and AC Immune’s Alzheimer’s jabhttps://pharmaphorum.com/news/early-data-back-jj-and-ac-immunes-alzheimers-jab/
BMS’ MS pill gets funding in Scotland after rejection in England by NICEScotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide Share XBMS’ MS pill gets funding in Scotland after rejection in England by NICEhttps://pharmaphorum.com/news/bms-ms-pill-gets-funding-in-scotland-after-rejection-in-england-by-nice/
Competition for Neurocrine as Gocovri picks up new Parkinson’s indicationAdamas Pharmaceuticals’ Parkinson’s drug Gocovri has a new indication as an adjunctive treatment for levodopa/carbodopa in patients with Share XCompetition for Neurocrine as Gocovri picks up new Parkinson’s indicationhttps://pharmaphorum.com/news/competition-for-neurocrine-as-gocovri-picks-up-new-parkinsons-indication/
Biogen shares soar as FDA delays decision on aducanumabThe FDA has delayed its decision on aducanumab, the troubled Alzheimer’s drug from Biogen and Eisai by three Share XBiogen shares soar as FDA delays decision on aducanumabhttps://pharmaphorum.com/news/biogen-shares-soar-as-fda-delays-decision-on-aducanumab/
